http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021023809-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0188cf0f35f6fb550c7592adfe8aca18 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
filingDate | 2020-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b31a8d0739785f569039b9eb790425ac |
publicationDate | 2021-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2021023809-A1 |
titleOfInvention | Etifoxine for use in the treatment of diseases related to activated mast cells |
abstract | The present application relates to Etifoxine, or a pharmaceutically acceptable derivative thereof for use in the treatment of a disease related to activated mast cells in a subject, preferably a human. Furthermore, the present application relates to a pharmaceutical composition comprising Etifoxine, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable excipient for use in the treatment of a disease related to activated mast cells. The present application further relates to an in vitro or ex-vivo method of inhibiting mast cell activation, comprising contacting a cell with Etifoxine, or a pharmaceutically acceptable derivative thereof. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023084198-A1 |
priorityDate | 2019-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 3785.